Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced new positive results from its ongoing Phase 2 open-label extension (OLE) study with fitusiran ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE